When the Municipal Bureau of supervision and administration of the people's Republic of China again launched a bid to raise the price of chlorpheniramine API, an enterprise was fined more than 10 million yuan
-
Last Update: 2018-12-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On December 28, Erkang pharmaceutical announced that its wholly-owned subsidiary Erkang pharmaceutical had received the notice of administrative penalty issued by the State Administration of market supervision The State Administration of market supervision and administration of the people's Republic of China has determined that Erkang pharmaceutical business has a dominant market position in China's chlorpheniramine API Market and is suspected of abusing its dominant market position by selling goods at an unfair high price Order Erkang pharmaceutical business to stop the illegal act immediately; confiscate the illegal income of 2.3947 million; and fine 8.4794 million After the incident, the company attached great importance to it and ordered Erkang pharmaceutical business to immediately organize rectification as required At present, the production and operation of the company and its subsidiaries are normal The full text of the announcement is as follows:
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
